Home > About Polpharma

ABOUT POLPHARMA GROUP

ABOUT POLPHARMA GROUP

ON KEY FACTS AND FIGURES

Polpharma Group is a leading regional (CEE and CIS) manufacturer of pharmaceuticals. Actively operating in the markets of Central and Eastern Europe, the Caucasus, and Central Asia.

For over 80 years, trusted by patients, healthcare professionals, and business partners alike, offering modern medicines, substances, and innovative solutions for patients and business partners from all over the world. 400 million medicines packages are made in our factories every year and commercialized directly or through a network of partners in more than 40 geographies globally.

With around more than 7,000 dedicated employees, Polpharma Group generates net revenues of more than EUR 1.2bn annually.

ON KEY FACTS AND FIGURES

Polpharma Group B.V. is headquartered in Amsterdam, The Netherlands. The group offers a broad range of prescription and non-prescription consumer healthcare products. As a leading regional (CEE and CIS) manufacturer of pharmaceuticals, Polpharma is actively operating in the markets of Central and Eastern Europe, the Caucasus and Central Asia with distribution and out-licensing partners in more than 40 markets globally.

In the financial year 2020, Polpharma achieved group sales of more than EUR 900 million globally. As of 31 December 2020, Polpharma employed more than 7,300 people worldwide.

0

YEARS OF EXPERIENCE & EXPERTISE

Since 1935 in Poland and since
1936 in Russia we have been
helping patients live long and
healthy lives

> 0

EMPLOYEES

Our leaders and top-class
specialists are a key success factor
in our long-term development

0

MANUFACTURING PLANTS

We have a network of state-of the
art production plants in Poland,
Kazakhstan and Russia

0

R&D CENTERS

We develop drugs at 5 R&D
centers

0

YEARS OF EXPERIENCE & EXPERTISE

Since 1935 in Poland and since
1936 in Russia we have been
helping patients live long and
healthy lives

> 0

EMPLOYEES

Our leaders and top-class
specialists are a key success factor
in our long-term development

0

MANUFACTURING PLANS

We have a network of state-of the
art production plants in Poland,
Kazakhstan and Russia

0

R&D CENTERS

We develop drugs at 5 R&D
centers

> 0

PRODUCTS BEING SOLD

> 0

PRODUCTS IN DEVELOPMENT

0 %

OF RX PRODUCTS

0 %

OF CHC PRODUCTS

> 0

PRODUCTS BEING SOLD

> 0

PRODUCTS IN DEVELOPMENT

0 %

OF RX PRODUCTS

0 %

OF CHC PRODUCTS

We produce affordable, accessible and safe medicines for the treatment
of civilisation diseases and for use as life-saving therapies

We have a balanced portfolio of Rx (prescription) and OTC (over-thecounter) products across specific therapeutic areas

Every day we diligently cooperate with doctors, pharmacists and other
healthcare professionals to better understand every stage of a patient’s
journey and ensure that our patients receive and stick to the most
adequate treatment.
Thanks to best-in-class industry talents and state-of-the-art technologies,
we are able to design and deliver crucial products and solutions to address
the biggest health challenges (an ageing population, chronic diseases)
and healthcare system problems (increasing healthcare costs, resource
shortages).
Through collaboration with our partners, we explore new ways of doing
business and accelerate positive changes.

At Polpharma Group, all our efforts are focused on
delivering high-quality and affordable medicines to
as many communities as possible.

OUR FOUNDATION

OUR FOUNDATION

At Polpharma Group, all our efforts are focused on delivering high-quality and affordable medicines to as many communities as possible.

Every day we diligently cooperate with doctors, pharmacists and other healthcare professionals to better understand every stage of a patient’s
journey and ensure that our patients receive and stick to the most adequate treatment.
Thanks to best-in-class industry talents and state-of-the-art technologies, we are able to design and deliver crucial products and solutions to address the biggest health challenges (an ageing population, chronic diseases) and healthcare system problems (increasing healthcare costs, resource shortages). Through collaboration with our partners, we explore new ways of doing
business and accelerate positive changes.

We are guided by more than just business results and
ambitious goals – OUR PURPOSE that constantly motivates
us and drives our actions and further development.

Helping people to live a healthy life in a healthy world

OUR PURPOSE

We are guided by more than just business results and ambitious goals – OUR PURPOSE that constantly motivates us and drives our actions and further development.

OUR PURPOSE

Helping people to live a healthy life in a healthy world

PEOPLE

Our foundations are helping people to
receive access to high-quality affordable
medicines and making them live
healthier. We want to inspire people by
engaging, motivating and educating
them.

HELPING

LIFE

Healthy life is the most precious thing
we have. With a strong emphasis on
accompanying the patient throughout
the whole “patient journey”, we
encourage people to focus on prevention
first. If treatment is needed, we provide
appropriate cures.

HEALTHY

WORLD

As we all want to live in a healthy world,
at Polpharma Group we protect the climate,
environment and available resources
by following the UN Sustainable
Development Goals. The world we strive
for is based on human rights, equal
opportunities, respect for all and the
highest ethical standards.

HEALTHY

HELPING

PEOPLE

Our foundations are helping people to receive access to high-quality affordable medicines and making them live healthier. We want to inspire people by engaging, motivating and educating them.

HEALTHY

LIFE

Healthy life is the most precious thing we have. With a strong emphasis on accompanying the patient throughout the whole “patient journey”, we encourage people to focus on prevention first. If treatment is needed, we provide appropriate cures.

HEALTHY

WORLD

As we all want to live in a healthy world, at Polpharma we protect the climate, environment and available resources by following the UN Sustainable Development Goals. The world we strive for is based on human rights, equal opportunities, respect for all and the highest ethical standards.

VISION

To continuously outgrow the healthcare market as a focused,
innovative and efficient team

VISION

To continuously outgrow the healthcare market as a focused, innovative and efficient team

CULTURE AS ACCELERATOR

COMMERCIALIZATION
LEADERSHIP

  • Polpharma Group cultural transformation program to
    further develop our company culture in line with our
    purpose and vision
  • Group talent development & retention

COST LEADERSHIP THROUGH
CONTINUOUS EFFICIENCY
& EFFECTIVENESS GAINS

  • Cost Leadership Program (OPEX and CoGS)
  • Program focused on supplier reliability (supply reliability,
    incl. ESO
  • Visibility & Control (CAPEX, OPEX spend control, KPIs)

INNOVATION AS PORTFOLIO DRIVER

  • Deliver on planned launches (on-time & in full)
  • BD partnering & strategic partnership acceleration to offer
    an even broader ranger of products
  • Day-1 launches
  • Transformation to a hybrid commercial model
  • Accelerate expansion of our Consumer Healthcare Brand business

4 STRATEGIC PRIORITIES

4 STRATEGIC PRIORITIES

INNOVATION AS PORTFOLIO DRIVER

  • Deliver on planned launches (on-time & in full)
  • BD partnering & strategic partnership acceleration to offer an even broader ranger of products

COST LEADERSHIP THROUGH CONTINUOUS EFFICIENCY & EFFECTIVENESS GAINS

  • Cost Leadership Program (OPEX and CoGS)
  • Program focused on supplier reliability (supply reliability, incl. ESO
  • Visibility & Control (CAPEX, OPEX spend control, KPIs)

CULTURE AS ACCELERATOR

  • Polpharma Group cultural transformation program to further develop our company culture in line with our purpose and vision
  • Group talent development & retention

COMMERCIALIZATION LEADERSHIP

  • Day-1 launches
  • Transformation to a hybrid commercial model
  • Accelerate expansion of our Consumer Healthcare Brand business
Markus Sieger

LEADERSHIP TEAM

MARKUS SIEGER

in

For over 20 years, Markus has been involved with Polpharma Group and
has held a range of leadership roles, including Member of Supervisory
Board, and since 2016 Chief Executive Officer.
He is committed to accelerate the long-term growth of the Polpharma
Group through constant development and empowerment of the
employees, digital transformation and strategic partnerships. Markus
is a seasoned entrepreneur and senior executive in different industries,
from information technology and digital media to fast moving consumer
goods, engineering and the healthcare industry. In 2018, he joined the
Executive Committee of Medicines for Europe, where he is driving the
digital transformation agenda.

CEO of Polpharma group

LEADERSHIP TEAM

in

Markus Sieger

MARKUS SIEGER

CEO of Polpharma group

For over 20 years, Markus has been involved with Polpharma Group and has held a range of leadership roles, including Member of Supervisory Board, and since 2016 Chief Executive Officer. He is committed to accelerate the long-term growth of the Polpharma Group through constant development and empowerment of the employees, digital transformation and strategic partnerships. Markus is a seasoned entrepreneur and senior executive in different industries, from information technology and digital media to fast moving consumer goods, engineering and the healthcare industry. In 2018, he joined the Executive Committee of Medicines for Europe, where he is driving the digital transformation agenda.

in

SIMON CLARK

Head of Commercial

MANAGEMENT

in

THOMAS NOTHEGGER

Head of Industrial Operations & Quality

in

ROBERT KNERR

Head of Business Development and R&D

MANAGEMENT

in

SIMON CLARK

Head of Commercial

in

THOMAS NOTHEGGER

Head of Industrial Operations & Quality

in

ROBERT KNERR

Head of Business Development and R&D

in

MACIEJ MIKUCKI

Polpharma Group CFO

in

CHRISTIAN LUDWIG

Head of Strategy

in

MACIEJ MIKUCKI

Polpharma Group CFO

in

CHRISTIAN LUDWIG

Head of Strategy

HANSPETER SPEK

Chairman of the Supervisory Board

SUPERVISORY BOARD

MARYNIKA
WOROSYLSKA-SAPIEHA

Member of the Supervisory Board

PETER PROCK

Member of the Supervisory Board

SUPERVISORY BOARD

HANSPETER SPEK

Chairman of the Supervisory Board

MARYNIKA
WOROSYLSKA-SAPIEHA

Member of the Supervisory Board

PETER PROCK

Member of the Supervisory Board

HISTORY

More than 85 years ago, a citizen of the Free City of Gdansk, Kurt Boskamp, founded the “Polpharma” Polish Chemical and Pharmaceutical Factory on the premises of a former agricultural machinery factory.
Since then, many years of work for patients has followed. Polpharma is now the leader of the Polish pharmaceutical market, is one of the largest generic companies in the world, and is still developing dynamically so that patients can take care of their health and attain long life.

HISTORY

More than 85 years ago, a citizen of the Free City of Gdansk, Kurt Boskamp, founded the “Polpharma” Polish Chemical and Pharmaceutical Factory on the premises of a former agricultural machinery factory. Since then, many years of work for patients has followed. Polpharma is now the leader of the Polish pharmaceutical market, is one of the largest generic companies in the world, and is still developing dynamically so that patients can take care of their health and attain long life.

Simon Clark

SIMON CLARK

Head of Commercial

Simon Clark graduated from the Royal Agricultural College in the UK and obtained a Higher National Diploma in Agricultural Science and Economics. He is an accomplished commercial executive with vast and long-term experience in fast-moving consumer goods, consumer healthcare (OTC) and pharmaceuticals. He has over 20 years of in-depth experience in the pharmaceutical sector in different region-al roles, covering both Northern Europe & Scandinavia and Central & Eastern Europe (including Russia and Poland), gained in multinational companies. He is responsible for the development and execution of commercial strategy for all subsidiaries of Polpharma Group by accelerating organic growth and acquisitions and developing strategic partnerships.

Thomas Nothegger

THOMAS NOTHEGGER

Head of Industrial Operations & Quality

Thomas Nothegger is a chemist by education (PhD, University of Innsbruck)
and a graduate of business administration (MBA, Management Center Innsbruck).
He has broad experience in Technical Operations, Product Development, Portfolio Management and Quality Management with a proven track record of acknowledged turnarounds. He has successfully developed and executed customer-centric strategies together with commercial operations. He gained international experience in Europe,
the US, Latin America, and Asia in multinational pharmaceutical companies.

Robert Knerr

ROBERT KNERR

Head of Business Development and R&D

Dr. Robert Knerr is a pharmacist by education (PhD in Pharmaceutical Technology)
and a graduate of business administration (MBA, Pharma Management,
International School of Management in Dortmund). He is a Qualified Person according
to EU GMP legislation. Active in the pharmaceutical industry for over 15 years,
Robert is a seasoned pharma executive with many years of experience in R+D,
Industrial Operations, Portfolio and Product Development in Stada and Haupt Pharma (now Aenova). Before joining Polpharma Group in 2021, Robert held a range
of leadership roles, including the most recent one as Executive Vice President
Global Portfolio and Product Development at Stada.

Maciek Mikucki

Maciej Mikucki

Chief Financial Officer

Maciej Mikucki is Polpharma’s Group Chief Financial Officer since September 2021.
Prior to joining Polpharma, he headed regional finance at Provident, a consumer lender.
In his career Maciej spent 9 years with pharmaceutical industry, working for Adamed (midcap regional player) as Group CFO (2016-2017) and Teva Pharmaceuticals as
CFO Poland (2008-2012) and later as Regional CFO responsible for Central & Eastern Europe (2013-2016). Between 2002 and 2007 he worked for The Coca-Cola Company (in Hungary, Poland and Australia), on positions of increasing responsibility leading to
the role of Regional Finance Director, Australia & New Zealand. Earlier in his career
Maciej worked for companies like Seagram, Polglass or Benckiser.
Polish national, fluent in English and intermediate in Russian, gained substantial
regional and remote management skills as well as restructuring /
business development exposure while working in pharmaceutical, FMCG, B2B and consulting industries. Maciej has a PhD in Economics (2018) and was an Assistant Professor at University of Social Sciences and Humanities (SWPS) in Warsaw.

Christian Ludwig

Christian Ludwig

Polpharma’s Group Head of Strategy

Christian Ludwig is Polpharma’s Group Head of Strategy since April 2021.
Prior to joining Polpharma, he was a Vice President of Strategy & Innovation
at STADA AG, leading the strategy, business intelligence and analytics functions.
Prior to this, Christian worked for McKinsey & Company as consultant in the Healthcare industry. For 9 years he has worked for leading European Generics companies
and private equity firms seeking investments in the broader healthcare space.
Christian has a BsC (Honors) Financial in Economics from (St Andrews University,UK)
and an MBA from ESADE Business School (Barcelona, Spain).

Hanspeter Spek

Hanspeter Spek

Chairman of the Supervisory Board

He started his career at Pfizer. Later he held several executive positions
in Sanofi, including GM for Germany, VP Executive for Europe and CEE,
the USA, Member of the Sanofi Executive Committee and President of Global
Pharma and Veterinary. Currently, he is an adviser on international projects
in the healthcare industry for pharma companies and private equity funds.

Marynika Woroszylska-Sapieha

Marynika Woroszylska-Sapieha

Member of the Supervisory Board

Over 20 years of experience in the pharmaceutical sector. Broad experience
in management, leadership, restructuring and post-merger integration.
President of the Board of Sanofi Poland (2004-2016) and Nepentes Pharma
(2013-2016). Currently member of the Supervisory Board of Bank Zachodni WBK (Santander Group).

Peter Prock

Peter Prock

Member of the Supervisory Board

Active in the pharmaceutical industry for 25 years. Began his career at Sandoz,
held managerial positions in Spain, the United States and Germany. Also held key positions in Ratiopharm Group and Actavis Group. Now an owner of a consulting
and M&A investment boutique active in the pharma industry.